Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Mult Scler ; 17(6): 743-54, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21372112

ABSTRACT

BACKGROUND: Probiotic treatment strategy based on the hygiene hypothesis, such as administration of ova from the non-pathogenic helminth, Trichuris suis, (TSO) has proven safe and effective in autoimmune inflammatory bowel disease. OBJECTIVE: To study the safety and effects of TSO in a second autoimmune disease, multiple sclerosis (MS), we conducted the phase 1 Helminth-induced Immunomodulatory Therapy (HINT 1) study. METHODS: Five subjects with newly diagnosed, treatment-naive relapsing-remitting multiple sclerosis (RRMS) were given 2500 TSO orally every 2 weeks for 3 months in a baseline versus treatment control exploratory trial. RESULTS: The mean number of new gadolinium-enhancing magnetic resonance imaging (MRI) lesions (n-Gd+) fell from 6.6 at baseline to 2.0 at the end of TSO administration, and 2 months after TSO was discontinued, the mean number of n-Gd+ rose to 5.8. No significant adverse effects were observed. In preliminary immunological investigations, increases in the serum level of the cytokines IL-4 and IL-10 were noted in four of the five subjects. CONCLUSION: TSO was well tolerated in the first human study of this novel probiotic in RRMS, and favorable trends were observed in exploratory MRI and immunological assessments. Further investigations will be required to fully explore the safety, effects, and mechanism of action of this immunomodulatory treatment.


Subject(s)
Multiple Sclerosis, Relapsing-Remitting/therapy , Probiotics , Trichuris , Administration, Oral , Adult , Animals , Antibodies, Helminth/blood , Biomarkers/blood , Brain/pathology , C-Reactive Protein/metabolism , Female , Humans , Interleukin-10/blood , Interleukin-4/blood , Magnetic Resonance Imaging , Male , Multiple Sclerosis, Relapsing-Remitting/diagnosis , Multiple Sclerosis, Relapsing-Remitting/immunology , Pilot Projects , Probiotics/adverse effects , Time Factors , Treatment Outcome , Trichuris/immunology , Up-Regulation , Wisconsin , Young Adult
2.
Brain ; 123 ( Pt 6): 1092-101, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10825349

ABSTRACT

Activated CD4 Th1 lymphocytes can enter the brain in the absence of an inflammatory focus. However, the molecular mediators that regulate this early migration of lymphocytes into the brain have remained unclear. We hypothesized that the entry of these 'pioneer' lymphocytes into the brain is regulated by a set of molecular events that are distinct from those used once inflammation has been established. Using cells fluorescently labelled with the lipophilic dye DiI, myelin basic protein (MBP)-specific CD4 lymphocytes that expressed low or high levels of very late antigen-4 (VLA-4) and non-antigen-specific activated splenocytes homed to mouse brain in similar quantities 2 h after adoptive transfer. However, antigen specificity and VLA-4 expression were required for more robust recruitment by 24 h. Immunocytochemistry revealed endothelial and microenvironmental upregulation of vascular cell adhesion molecule (VCAM), intercellular cell adhesion molecule 1 (ICAM-1), MHC class II and interferon-gamma 48 h after transfer of MBP-specific cells. In contrast, expression of meningeal and choroid plexus-associated P selectin was upregulated 2 h after adoptive transfer, but not at 48 h. Monoclonal antibody to P selectin, but not to VLA-4, inhibited early migration of high VLA-4-expressing MBP-specific lymphocytes. These results suggest that early migration occurs independent of the lymphocyte integrin VLA-4 and endothelial VCAM, but does require increased surface expression of endothelial P selectin.


Subject(s)
Brain Chemistry/immunology , Encephalomyelitis, Autoimmune, Experimental/immunology , Immunologic Surveillance , Integrins/immunology , Receptors, Lymphocyte Homing/immunology , Vascular Cell Adhesion Molecule-1/immunology , Animals , Anti-Allergic Agents/immunology , Anti-Allergic Agents/metabolism , Antibodies, Monoclonal , Brain/cytology , Brain/immunology , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , Carbocyanines , Cell Movement/immunology , Encephalomyelitis, Autoimmune, Experimental/metabolism , Female , Fluorescent Dyes , Histocompatibility Antigens Class II/immunology , Integrin alpha4beta1 , Integrins/metabolism , Intercellular Adhesion Molecule-1/immunology , Intercellular Adhesion Molecule-1/metabolism , Interferon-gamma/immunology , Mice , Mice, Inbred Strains , Myelin Basic Protein/immunology , P-Selectin/immunology , Pancreas/cytology , Pancreas/immunology , Receptors, Lymphocyte Homing/metabolism , Spleen/cytology , Th1 Cells/cytology , Th1 Cells/immunology , Vascular Cell Adhesion Molecule-1/metabolism
3.
Chem Biol ; 3(7): 537-42, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8807885

ABSTRACT

BACKGROUND: Through the effects of avidity, multivalency can increase the apparent affinity of a ligand for its binding site. Low molecular weight, high affinity, multivalent ligands theoretically could be used to deliver a variety of agents to specific cell subtypes. In order to target specific G-protein-coupled receptors, a series of monospecific peptide dimers were synthesized that are designed to bind to two adjacent receptor sites. RESULTS: Three dimers, consisting of a ligand region, a short, flexible, uncharged spacer, a longer, polylysine spacer and a single cysteine residue to permit dimerization, and the corresponding monomers were synthesized by solid-phase peptide synthesis. The ligand domain was either alpha-melanocyte stimulating hormone (alpha-MSH), an alpha-MSH receptor antagonist (alpha-MSH-ANT), or bombesin. These ligands were characterized in a functional melanocyte dispersion assay. In wild-type melanophores, the alpha-MSH dimer stimulated dispersion with an EC50 approximately seven-fold lower than that of the corresponding monomer. Similarly, in cells transfected with bombesin receptor cDNA, the bombesin dimer was approximately five-fold more potent than the monomer. The alpha-MSH-ANT monomer specifically inhibited alpha-MSH-mediated dispersion with no significant agonist activity, but the dimer acted predominantly as an agonist. CONCLUSIONS: Peptide dimers can be synthesized easily and have enhanced functional activity; monospecific dimers have greater avidity and bispecific dimers are likely to have greater selectivity. They may therefore have practical potential as specific cell-targeting agents.


Subject(s)
GTP-Binding Proteins/metabolism , Peptides/chemistry , Peptides/metabolism , Receptors, Cell Surface/metabolism , Amino Acid Sequence , Animals , Binding Sites , Bombesin/chemistry , Bombesin/metabolism , Dimerization , In Vitro Techniques , Ligands , Melanocytes/metabolism , Molecular Sequence Data , Molecular Structure , Peptides/chemical synthesis , Receptors, Bombesin/genetics , Receptors, Bombesin/metabolism , Transfection , Xenopus laevis , alpha-MSH/antagonists & inhibitors , alpha-MSH/metabolism
4.
Neurosci Lett ; 135(1): 45-8, 1992 Jan 20.
Article in English | MEDLINE | ID: mdl-1542436

ABSTRACT

The binding characteristics of [125I]angiotensin II (ANG II) to membranes prepared from undifferentiated and differentiated neuroblastoma x glioma hybrid cells (NG108-15) were investigated. Scatchard analysis revealed the existence of high and low affinity sites in differentiated cells, but only a low affinity site in undifferentiated cells. Similarly, self-displacement studies revealed competition to a single low affinity site in undifferentiated cells, and to high and low affinity sites in differentiated cells. Angiotensin III (ANG III) displaced high affinity binding in differentiated cells but did not displace low affinity binding in either differentiated or undifferentiated cells. Furthermore, 5-guanyl imidodiphosphate (GPP(NH)P) inhibited [125I]ANG II binding to differentiated cells, in a dose-dependent fashion, but had no effect on binding to indifferentiated cells. These findings suggest that the high affinity site represents a G-protein linked receptor with approximately equal affinities for ANG II and ANG III. We hypothesize that the low affinity site represents a non-specific membrane-bound aminopeptidase.


Subject(s)
Angiotensin II/metabolism , Guanylyl Imidodiphosphate/pharmacology , Receptors, Angiotensin/metabolism , Animals , Binding, Competitive , Cell Differentiation , Cell Membrane/metabolism , GTP-Binding Proteins/metabolism , Glioma , Hybrid Cells/cytology , Hybrid Cells/metabolism , Kinetics , Mice , Neuroblastoma , Rats , Receptors, Angiotensin/drug effects
5.
Biochem Biophys Res Commun ; 170(3): 1096-101, 1990 Aug 16.
Article in English | MEDLINE | ID: mdl-2390077

ABSTRACT

Neuroblastoma x glioma hybrid cells (NG108-15) were used as a model system to characterize neuronal-glial type angiotensin (ANG) receptors by covalent crosslinking analysis. After differentiation with 1.5% DMSO and 0.5% fetal bovine serum for four to five days, saturation analysis revealed a single high affinity site with a Kd = 1.35 +/- 0.42 nM and a Bmax = 468 +/- 106 fmol/mg protein. Using the homobifunctional crosslinking reagent bis(sulfosuccinimidyl) suberate (BS3), a site with an estimated Mr of 78 kDa was specifically labeled with 125I-ANG II as determined by SDS-polyacrylamide gel electrophoresis. Both ANG II and ANG III (10(-6) M) inhibited specific labeling. The Ki for ANG III binding was similar by both pharmacologic (Ki = 3.33 +/- 0.98 nM) and gel densitometric (Ki = 2.65 +/- 0.32 nM) analyses. We conclude that the 78 kDa protein represents a high affinity ANG binding site with similar affinities for both ANG II and ANG III.


Subject(s)
Cross-Linking Reagents/pharmacology , Glioma/metabolism , Neuroblastoma/metabolism , Receptors, Angiotensin/metabolism , Succinimides/pharmacology , Binding Sites , Cell Differentiation , Tumor Cells, Cultured/metabolism
6.
Biochem Biophys Res Commun ; 167(3): 1200-5, 1990 Mar 30.
Article in English | MEDLINE | ID: mdl-2322266

ABSTRACT

Neuroblastoma x glioma hybrid cells (NG108-15), differentiated by treatment with 1.5% dimethyl sulfoxide (DMSO) and 0.5% fetal bovine serum, were used to measure the effect of angiotensin II and III (ANG II and ANG III) on the generation of inositol polyphosphates. ANG II increased the synthesis of inositol monophosphates (IP1), inositol diphosphates (IP2), and inositol trisphosphates (IP3) with maximal responses observed at 300, 120, and 30 sec, respectively. The percent increases above basal values at the maximal responses were 140% +/- 9% (IP1), 142% +/- 4% (IP2), and 132% +/- 4% (IP3). This effect was not attenuated by pretreatment of the cells with pertussis toxin. Furthermore, both ANG II and ANG III increased the production of inositol polyphosphates in a dose-dependent manner with ED50 values of 145 nM and 11 nM, respectively. We conclude that differentiated NG108-15 cells express an ANG III selective receptor that mediates phosphatidylinositol breakdown through a pertussis toxin insensitive G-protein.


Subject(s)
Angiotensin III/pharmacology , Angiotensin II/analogs & derivatives , Angiotensin II/pharmacology , Hybrid Cells/metabolism , Inositol Phosphates/metabolism , Animals , Cell Differentiation , Cell Line , Glioma , Hybrid Cells/cytology , Hybrid Cells/drug effects , Inositol/metabolism , Kinetics , Mice , Neuroblastoma , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...